STONEBRANCH
9.4.2024 15:01:34 CEST | Business Wire | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today published the 2024 Global State of IT Automation Report: IT Automation and Orchestration Benchmarks for IT Ops, DevOps, CloudOps, and DataOps Teams, its third-annual benchmark study on the automation priorities, expectations, and challenges of IT professionals worldwide.
“We're pleased to release our Global State of IT Automation Report, now in its third year,” said Giuseppe Damiani, Stonebranch CEO. “This research offers a detailed analysis of current trends, challenges, and opportunities in IT automation and orchestration, providing valuable benchmarks for IT professionals worldwide. We're passionate about contributing to the IT industry's evolution and innovation, and we're dedicated to helping our customers realize their automation potential.”
Key Insights from the 2024 Global State of IT Automation Report
The 2024 Global State of IT Automation Report is based on a survey of IT automation professionals and executives, conducted by Censuswide between January 24 – February 5, 2024.
This year's report unveils critical insights into the evolving landscape of IT automation, offering a unique lens through which IT Ops, DevOps, CloudOps, and DataOps professionals can view the future of automation and orchestration technologies. Three notable emerging trends include:
- Automation is Evolving into Orchestration: Driven by a desire to orchestrate across complex hybrid IT environments, 82% of respondents plan to replace legacy IT automation tools or add new automation tools to the mix.
- Democratization of Automation Continues to Grow: 88% of respondents enable end-users across the business with self-service access to IT automation. Those who plan to add or replace IT automation tools with a more modern solution cited a desire to add self-service as the leading reason for change.
- Companies Prefer a Mix of On-Prem and Cloud Environments: In only one year, hybrid IT usage has doubled from 34% to 68%. Organizations are deciding where to store data — either on-prem or cloud — on a case-by-case basis. This approach is efficient and flexible but poses a challenge when it comes to automating and orchestrating these environments.
- Machine Learning Pipelines are Evolving and Growing in Importance: A significant 74% of respondents have already incorporated data and ML pipelines to operationalize their AI-driven initiatives. This is an indicator of many companies’ strong commitment to the pivotal role of AI in shaping their future success.
Peter Baljet, Stonebranch CTO, notes, “Our findings show that companies are adapting their IT automation and orchestration strategies to meet the specific challenges that come with cloud technologies. In the complex world of today’s hybrid IT environments, automation is crucial to enhance performance, secure systems, and control costs.”
To fully explore the research results:
- Download the full report — Stonebranch 2024 Global State of IT Automation: IT Automation and Orchestration Benchmarks for IT Ops, DevOps, CloudOps, and DataOps Teams.
- Watch the research results webinar, which highlights key trends and insights from the report, as well as Stonebranch’s recommendations for success.
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Center platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409835235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom